Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in Shanghai, China, Panlin Capital is a venture capital firm specializing in healthcare and biotechnology. The firm targets investments in innovative companies, particularly in life sciences and technology services. Their focus spans various stages, from pre-seed to growth equity, with a commitment to addressing significant clinical challenges.
Panlin Capital invests in companies that develop innovative solutions for unmet clinical needs in major diseases, emphasizing drug development and medical device research. They also target B2B enterprises that enhance operational efficiency and ensure technology autonomy. Investment sizes and specific check amounts are not disclosed.
Notable portfolio companies include 康泰生物 (Kangtai Biological), a leading vaccine company in China; 极米科技 (XGIMI), the first publicly listed smart projector company in China; and 凯普生物 (Capbio), a leader in cervical cancer screening. Other investments include 瑞博生物 (Rebio), 劲方医药 (JinFang Pharmaceutical), 亚飞生物 (Afei Biotech), 透彻未来 (TuoChe Future), 奇捷科技 (Qijie Technology), and 丹擎医药 (Danqing Pharmaceutical).
To pitch Panlin Capital, email your deck to master@panlincap.com.
Panlin Capital invests across various stages, including pre-seed, seed, seed+, Series A, Series B, and growth equity.
The firm primarily focuses on healthcare and biotechnology, targeting companies that address unmet clinical needs through innovative solutions.
Founders can submit their pitch via email to master@panlincap.com.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.